US WorldMeds, LLC Release: New Clinical Trial Investigates APOKYN for Treating Debilitating Morning Akinesia in Parkinson’s Disease Patients
5/13/2013 9:58:07 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOUISVILLE, Ky.--(BUSINESS WIRE)--US WorldMeds today announced the launch of a new clinical trial investigating APOKYN® (apomorphine hydrochloride injection) as a rapid and reliable treatment for “morning akinesia” in Parkinson’s disease. AM IMPAKT, short for Apokyn for Motor IMProvement of Morning AKinesia Trial, is a Phase IV, multi-center, open-label study that will enroll approximately 100 subjects at 12 study sites across the US.
Help employers find you! Check out all the jobs and post your resume.
comments powered by